Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Aktis launches with $72 million for cancer radiotherapy
by Michael McCoy
March 20, 2021
| A version of this story appeared in
Volume 99, Issue 10
Aktis Oncology has launched with $72 million in series A financing to develop radiopharmaceuticals for cancer. The start-up was founded and incubated by the venture capital firm MPM Capital. Aktis is developing targeted therapies that use α-particle-emitting radioisotopes to kill cancer cells. Many traditional radiotherapies use β particles, which are lower energy and travel farther in the body, causing unwanted damage. Five venture capital firms, including MPM, and the drug companies Novartis and Bristol Myers Squibb contributed to the financing.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X